Journal Publications, General

Billiar, K., Murray, J., Laude, D., Abraham, G., and Bachrach, N., "Effects of Carbodiimide Crosslinking Conditions on the Physical Properties of Laminated Intestinal Submucosa," Journal of Biomedical Materials Research , 56 (1), July 2001: 101-108.

Laning, J.C., DeLuca, J.E., Isaacs, C.M., and Hardin-Young, J., "In Vitro Analysis of CD40-CD154 and CD28-CD80/86 Interactions in the Primary T-Cell Response to Allogeneic "Nonprofessional" Antigen Presenting Cells," Transplantation , 71 (10), May 2001: 1467-1474.

Gloeckner, D.C., Sacks, M.S. Billiar, K.L., and Bachrach N., "Mechanical Evaluation and Design of a Multi-layered Collagenous Repair Biomaterial," Journal of Biomedical Material Research , 52 (2), November 2000: 365-373.

Behnia, K., Sangeeta, B., Jastromb, N., Balis, U., Sullivan, S., Yarmush, M., and Toner M., "Xenobiotic Metabolism by Cultured Primary Porcine Hepatocytes," Tissue Engineering , 6 (5), October 2000: 467-479.

Abraham, G.A., Murray, J., Billiar, K., and Sullivan, S.J., "Evaluation of the Porcine Intestinal Collagen Layer as a Biomaterial," Journal of Biomedical Material Research , 51 (3), September 2000: 442-452.

Laude, D., Odlum, K., Rudnicki, S., and Bachrach, N., "A Novel Injectable Collagen Matrix: In Vitro Characterization and In Vivo Evaluation," Journal of Biomechanical Engineering , 122 (3), June 2000: 231-235.

Gregory, P.G., Connolly C.K., Toner, M., and Sullivan, S.J., "In Vitro Characterization of Porcine Hepatocyte Function," Cell Transplantation , 9 (1), January/February 2000: 1-10.

Huynh, T., Abraham, G., Murray, J., Brockbank, K., Hagen, P. and Sullivan, S., "Remodeling of an Acellular Collagen Graft into a Physiologically Responsive Neovessel," Nature Biotechnology , 17 (11), November 1999: 1083-6.

Briscoe, D.M., Dharnidharka, V.R., Isaacs, C., Downing, G., Prosky, S., Shaw, P., Parenteau, N.L., Hardin-Young, J., "The Allogeneic Response to Cultured Human Skin Equivalent in the hu-PBL-SCID Mouse Model of Skin Rejection," Transplantation , 67 (12), June 1999: 1590-1599.

Moulton, K.S., Melder, R.J., Dharnidharka, V.R., Hardin-Young, J., Jain, R.K., Briscoe, D.M., " Angiogenesis in the huPBL-SCID Model of Human Transplant Rejection," Transplantation , 67 (12), June 1999: 1626-1631.

Gloeckner, D.C., Billiar, K.L., and Sacks, M.S., "Effects of Accelerated Durability Testing on the Bending Behavior of Bioprosthetic Aortic Heart Valve," ASAIO , 45 (1), January-February 1999: 59-63.

Balis, U., Behnia, K., Dwarakanath, B., Bhatia, S., Sullivan, S, Yarmush, M. and Toner, M., "Oxygen Consumption Characteristics of Porcine Hepatocytes," Metabolic Engineering 1 , 49-62 (1999).

Book Chapters, General

Sullivan, S., and Brockbank, K.G.M. Small-diameter Vascular Grafts. In: Lanza, R., Vacanti, J., Editors. Principles of Tissue Engineering , 2nd Edition. Academic Press, 2000, pp. 447-454.

Journal Publications, Apligraf®

No author listed. "Treatment of ulcers with Apligraf®." Krankenpfl J. 2002;40(1-2):32-3. (Article in German).

Alvarez OM, Fahey CB, Auletta MJ, Fernandez-Obregon A. "A novel treatment for venous leg ulcers." J Foot Ankle Surg. 1998 Jul-Aug;37(4):319-24.

Atillasoy E and Sabolinski ML. "Current and investigative uses of Graftskin (Apligaf®) in wound care: summary." Wounds 2000;12(5 Suppl A):78A-79A.

Banta MN, Kirsner RS. "Modulating diseased skin with tissue engineering: actinic purpura treated with Apligraf®." Dermatol Surg. 2002 Dec;28(12):1103-6.

Bello YM, Falabella AF. "The role of Graftskin (Apligraf®) in difficult-to-heal venous leg ulcers." J Wound Care 2002 May;11(5):182-3.

Brem H et al: "Healing of diabetic foot ulcers and pressure ulcers with human skin equivalent. A new paradigm in wound healing." Arch Surg 2000 June;135:627-634.

Brem H, Kirsner R. "Use of Graftskin (Apligraf®) in the treatment of pressure ulcers and acute wounds." Wounds 2000;12(5Suppl A):72A-77A.

Brem H, Balledux J, Sukkarieh T, Cason, P and Falanga V. "Healing of venous ulcers of long duration with a bi-layered living skin substitute: results from a general surgery and dermatology department." Dermatol Surg 2001;27:916-919.

Brem H, Balledux J, Sukkarieh T, Carson P, Falanga V. "Healing of venous ulcers of long duration with a bi-layered living skin substitute: results from a general surgery and dermatology department." Dermatol Surg 2001 Nov;27(11):915-9.

Brem H, Nierman DM, Nelson JE. "Pressure ulcers in the chronically critically ill patient." Crit Care Clin. 2001;18:683-694.

Brem H, Young J, Isaacs C, Tomic-Canic M, Ehrlich P. "Clinical efficacy and mechanisms of bi-layered living human skin equivalent (HSE) in treatment of diabetic foot ulcers." Surg Tech Internat XI May 2003:23-31.

Brem H, et al: "Wound healing protocols for diabetic foot and pressure ulcers." Surg Tech Internat XI May 2003: 85-92.

Brem H, et al: "Healing of elderly patients with diabetic foot ulcers, venous stasis ulcers, and pressure ulcers." Surg Tech Internat XI May 2003:161-167.

Briscoe DM, Dharnidharka VR, Isaacs C, Downing G, Prosky S, Shaw P, Parenteau NL, Hardin-Young J. "The allogeneic response to cultured human skin equivalent in the hu-PBL-SCID mouse model of skin rejection." Transplant 1999 June;67(12):1590-9.

Curran MP and Plosker GL. "Bi-layered bioengineered skin substitute (Apligraf®): a review of its use in the treatment of venous leg ulcers and diabetic foot ulcers." BioDrugs 2002;16(6): 439-55.

De SK, Reis ED and Kerstein MD. "Wound treatment with human skin equivalent." J Am Podiatr Med Assoc. 2002 Jan;92(1):19-23.

De Imus G, Golomb C, Wilkel C, et al. "Accelerated healing of pyoderma gangrenosum treated with bioengineered skin and concomitant immunosuppression." J Amer Acad of Derm 2001;44(1):61-66.

Delfanian K, Davis MDP, Kavros SJ, and Felty CL. "Application of living skin equivalent for the treatment of chronic lower-extremity ulcers recalcitrant to conventional therapeutic methods." Wound 2004;16(3):105-108.

Dolynchuk K, Hull P, Guenther L, Sibbald RG, Brassard A, Cooling M, Delorme L, Gulliver W, Bourassa DH, Ho V, Kunimoto B, Overholt T, Papp K and Tousignant J. "The role of Apligraf® in the treatment of venous leg ulcers." Ostomy Wound Manag. 1999 Jan;45(1):34-43.

Eaglstein WH, et al. "A composite skin substitute (Graftskin) for surgical wounds." Dermatol Surg 1995;21:839-843.

Eaglstein WH and Falanga V. "Tissue engineering and the development of Apligraf®, a human skin equivalent." Clin Ther. 1997 Sep-Oct;19(5):894-905.

Eaglstein WH and Falanga V. "Tissue engineering and the development of Apligraf®, a human skin equivalent." Cutis. 1998 Jul;62(1 Suppl):1-8.

Eaglstein WH and Falanga V. "Tissue engineering and the development of Apligraf® a human skin equivalent." Adv Wound Care 1998 Jul-Aug;11(4 Suppl):1-8.

Eaglstein W, et al: "Acute excisional wounds treated with a tissue-engineered skin (Apligraf®)." Derm Surg 1999;25:195-201.

Fahey C. "Experience with a new human skin equivalent for healing venous leg ulcers." J Vasc Nurs 1998 Mar;16(1):11-5.

Falabella AF, Schachner JA, Valencia JC, and Eaglstein WH. "The use of tissue-engineered skin (Apligraf®) to treat a newborn with epidermolysis bullosa." Arch Dermato. 1999 Oct;135(10):1219-22.

Falabella L and Eaglstein W: "Tissue-engineered skin (Apligraf®) in the healing of patients with epidermolysis bullosa wounds." Arch Dermatol 2000;136(10):1225-1230.

Falanga V and Eaglstein WH. "Management of venous ulcers." Am. Fam. Physician 1986;33:274-281.

Falanga V, Isaacs C, Paquette D, Downing G, Kouttab N, Butmarc J, Badiavas E, and Hardin Young J. "Wounding of bioengineered skin: cellular and molecuar aspects after injury." J Invest Dermato. 2002;119:653-660.

Falanga V, et al: "Rapid healing of venous ulcers and lack of clinical rejection with an allogeneic cultured human skin equivalent." Arch Dermatol 1998 ;134:293-300.

Falanga V. "Apligraf® treatment of venous ulcers and other chronic wounds." J of Dermato. 1998;25:812-817.

Falanga V, et al: "A New Cost Effective Therapy for the Treatment of Hard to Heal Venous Leg Ulcers." Wound Repair Regen 1998 May-June;6:3.

Falanga V. "How to use Apligraf® to treat venous ulcers." Skin & Aging 1999 February.

Falanga V and Sabolinski M. "A bi-layered living skin construct (Apligraf®) accelerates complete closure of hard-to-heal venous ulcers." Wound Repair Regen 1999;7(4):201-207.

Falanga V and Sabolinski ML. "Prognostic factors for healing of venous and diabetic ulcers," Wounds 2000;12(5 Suppl A):42A-46A.

Falanga V. "Bioengineered skin," Wounds 2000;12(6 Suppl B):99B-105B.

Falanga VJ. "Tissue engineering in wound repair." Adv Skin Wound Care 2000 May-Jun;13(2 Suppl):15-90.

Fivenson DP, Scherschun L, Choueair M, KuKuruga D, Young J and Shwayder T. "Graftskin therapy in epidermolysis bullosa." J Am Acad Dermato. 2003 June;48(6):886-92.

Fivenson DP, Scherschun L, and Cohen LV. "Apligraf® in the treatment of severe mitten deformity associated with recessive dystrophic epidermolysis bullosa." Plast Reconstr Surg 2003 Aug;112(2):584-8.

Fivenson D and Scherschun L. "Clinical and economic impact of Apligraf® for the treatment of nonhealing venous leg ulcers." Int J Dermatol 2003 Dec;42(12):960-5.

Flores F, Eaglstein WA, and Kirsner RS. "Hydroxyurea-induced leg ulcers treated with Apligraf®." Ann Intern Med 2000 Mar;132(5):417-8.

Guerret S, Govignon E, Hartmann DJ, Ronfard V. "Long-term remodeling of a bi-layered living human skin equivalent (Apligraf®) grafted onto nude mice: immunolocalization of human cells and characterization of extracellular matrix." Wound Repair Regen 2003 Jan-Feb;11(1):35-45.

Hansbrough JF, et al. "Evaluation of Graftskin composite grafts on full-thickness wounds on athymic mice." J. Burn Care Rehabil 1994;15:346-353.

Hardin Young J, Teumer J, Kemp PD and Parenteau NL. "Approaches to transplanting engineered cells and tissues." In: Lanza, R., Langer, R. and Chick, W., Editors. Principles of Tissue Engineering, R.G. Landes, 1997, pp. 297-307.

Hardin Young J, Teumer J, Ross RN and Parenteau NL. "Approaches to transplanting engineered cells and tissues." In: Lanza, R., Langer, R. and Vacanti, J., Editors. Principles of Tissue Engineering, 2nd Edition, Academic Press, 2000, pp. 281-291.

Hardin-Young J and Parenteau NL. "Bi-layered skin constructs." In Atala and Lanza (Eds.), Methods of Tissue Engineering, Academic Press, 2002, pp. 1177-1188.

Hayes Jr. DW Webb GE, Mandracchia VJ and John KJ. "Full-thickness burn of the foot: successful treatment with Apligraf®. A case report." Clin Podiatr Med Surg 2001 Jan; 18(1):179-88.

Horn WA. "Graftskin heals an ulcer on an amputation stump." Dermatol Surg 2000 Oct; 26(10):946-8.

Jansen DA, Asgari MM, Atillasoy ES and Milstone LM. "Clinical and in vitro responses of bi-layered skin construct (Graftskin) to meshing." Arch Dermatol 2002 Jun;138(6):843-4.

Kerstein Morris D, et al: "Development of a severity scale for evaluating the need for Graftskin in nonhealing Ulcers." Adv in Skin Wound Care 2002;15(2):66-71.

Kirsner RS. "The use of Apligraf® in acute wounds." J Dermatol 1998 Dec;25(12):805-11.

Kirsner RS, Fastenau J, Falabella A, Valencia I, Long R, and Eaglstein WH. "Clinical and economic outcomes with Graftskin for hard-to-heal venous leg ulcers: a single-center experience." Br J Nurs 2000 Oct;9 (19 Suppl):S6, S8, S10 passim.

Kirsner R, Falanga V, Fivenson D, Thibodeaux K, Cavorsi J, de la Pava D, Brem H, and Golomb CA. "Clinical experience with a human skin equivalent for the treatment of venous leg ulcers: Process and outcomes." Wounds 1999;11(6):137-144.

Krasner D and Kane D. Chronic wound care: A clinical sourcebook for healthcare professionals. Second Edition. Health Management Publications, Inc. Wayne, PA 1997.

Laning JC, DeLuca J and Hardin-Young J. "Effects of immunoregulatory cytokines on the immunogenic potential of the cellular components of a bi-layered living skin equivalent." Tissue Eng 1999;(5):171-179.

Lee KH. "Tissue-engineered human living skin substitutes: development and clinical application." Yonsei Med J 2000 Dec;41(6):774-9.

Lee DK and Serkin AL. "Carbon Dioxide laser and Apligraf® for a painful plantar hypertrophic scar." J of Amer Pod Med Assoc 2004 Jan/Feb;94(1):61-64.

Long RE, Falabella AF, Valencia I, Eaglstein WH and Kirsner RS. "Treatment of refractory, atypical lower extremity ulcers with tissue-engineered skin (Apligraf®)." Arch Dermatol 2001 Dec;137(12):1660-1.

Maier JP, Lippitt C and Mooney EK. "Use of tissue-engineered skin in the dermal atrophy patient with traumatic avulsion injuries." Ann Plast Surg 2002 Jul;49(1):67-72;discussion 72. Erratum in: Ann Plast Surg 2002 Aug;49(2):214.

Martin LK and Kirsner RS. "Ulcers caused by bullous morphea treated with tissue-engineered skin." Int J Dermatol 2003 May;42(5):402-4.

Masseth R. "Apligraf®: A promising new wound care treatment for the 21st century." J of Nat Assoc Ortho Tech, Spring 2002:22-25.

Mathias SD, Prebil LA, Boyko WL and Fastenau J. "Health-related quality of life in venous leg ulcer patients successfully treated with Apligraf®: a pilot study." Adv Skin Wound Care 2000;13(2):76-8.

Medina J, de Brugerolle de Fraissinette, Chibout SD, Kolopp M, Kammermann R, Burtin P, Ebelin ME and Cordier A. "Use of human skin equivalent Apligraf® for in vitro assessment of cumulative skin irritation potential of topical products." Toxicol Appl Pharmacol. 2000 Apr 1; 164(1):38-45.

Milstone L, Asgari M, Schwartz P and Hardin-Young J. "Growth factor expression, healing, and structural characteristics of Graftskin (Apligraf®)." Wounds 2000 Sept;12(5 Suppl A):12A-19A.

Moneta G. "Graftskin (Apligraf®) in the treatment of venous leg ulcer: optimal application techniques." Wounds 2000;12(5 Suppl A):27A-32A.

Mooney EK, Lippitt C, Reynolds R. "Alternate applications of living skin equivalent." Wounds 2002;14(7):257-265.

Moore J, Harkless L, and Liu G. "Preserving the diabetic foot." Podiatry Today 2001 December.

Muhart M, McFalls S, Kirsner RS, Elgart GW, Kerdel F, Sabolinski ML, Hardin-Young J, and Eaglstein WH. "Behavior of tissue-engineered skin: a comparison of a living skin equivalent, autograft, and occlusive dressing in human donor sites." Arch Dermatol 1999 Aug;135(8):913-8.

Noel B. "Economic assessment of Apligraf® for the treatment of venous leg ulcers." Wound Repair Regen 2001;9(1):60.

Nolte CJM, et al. "Ultrastructural features of composite skin cultures grafted onto athymic mice." J Anat 1994;185:325-333.

Osborne CS, Schmid P. "Epidermal-dermal interactions regulate gelatinase activity in Apligraf®, a tissue-engineered human skin equivalent." Br J Dermatol 2002;146(1):26-31.

Ozerdem OR, Wolfe SA and Marshall D. "Use of skin substitutes in pediatric patients." J Craniofac Surg 2003;14(4):517-20.

Parenteau N, et al. "Biological and physical factors influencing the successful engraftment of a cultured human skin substitute." Biotech Bioeng 1996;52:3-14.

Parenteau N, Sabolinski M, Mulder G and Rovee D. "Wound research." In: Krasner D., Kane D. Chronic Wound Care, Second Edition. Wayne, PA, Health Management Publications, Inc., 1997, pp. 389-395.

Parenteau N. "Skin: The first tissue-engineered products - The Organogenesis story." Scientif Amer April 1999.

Parenteau NL, Hardin Young J and Ross RN. "Skin." In: Lanza, R., Langer, R. and Vacanti, J., Editors. Principles of Tissue Engineering, 2nd Edition, Academic Press, 2000, pp. 879-890.

Pennoyer JW. "Ulcers associated with polyarteritis nodosa treated with bioengineered human skin equivalent (Apligraf®)." J Amer Acad of Derm 2002;46(1):145.

Pham HT, et al: "Evaluation of a human skin equivalent for the treatment of diabetic foot ulcers in a prospective, randomized, clinical trial." Wounds 1999;11(4):79-86.

Phillips J and Rockwell WB. "Surgical treatment of recessive dystrophic epidermolysis bullosa in the hand: use of tissue-engineered skin (Apligraf®)." Ann Plast Surg 2003 Apr; 50(4):441-2.

Phillips TJ. "New skin for old." Arch of Dermatol 1998;134:344-349.

Phillips TJ and Dover JS. "Leg ulcers." J Am Acad Dermatol 1991;25:965-987.

Phillips TJ, Manzoor J, Rojas A, Isaacs C, Carson P, Sabolinski M, Young J and Falanga V. "The longevity of a bi-layered skin substitute after application to venous ulcers." Arch Dermatol 2002;138(8):1079-81.

Phillips TJ. "Current approaches to venous ulcers and compression." Dermatol Surg 2001;27(7):611-21.

Phillips TJ. "Successful methods of treating leg ulcers. The tried and true, plus the novel and new." Postgrad Med. 1999;105(5):159-61, 165-6, 173-4 passim.

Pollak R. "Use of Graftskin (Apligraf®) in diabetic foot ulcers: case presentations." Wounds 2000;12(5 Suppl A):37A-41A.

Redekop WK, McDonnell J, Verboom P, Lovas K and Kalo Z. "The cost effectiveness of Apligraf® treatment of diabetic foot ulcers." Pharmacoeconom 2003;21(16):1171-83.

Sabolinski ML, et al: "Cultured skin as a smart material for healing wounds: Experience in venous ulcers." Biomat 1996;17:311-320.

Sabolinski ML and Veves A. "Graftskin (Apligraf®) in neuropathic diabetic foot ulcers." Wounds 2000;12(5 Suppl A):33A-36A.

Sabolinski ML and Bilbo PR. "The clinical experience of bioengineered skin products." In Falanga, V. (Ed.), Cutaneous Wound Healing, Martin Dunitz, 2001, pp. 411-431.

Sams HH, Chen J and King LE. "Graftskin treatment of difficult to heal diabetic foot ulcers: one center's experience." Dermatol Surg 2002 Aug;28(8):698-703.

Schachner L and Eaglstein W. "Baby is pioneer patient for new use of skin." Am Med News 1999;42(5):1.

Schmid P. "Immunohistologic characterization of Graftskin (Apligraf®)," Wounds , 2000 Sept; 12(5 Suppl A):4A-11A.

Schmid P, Grenet O, Medina J, Chibout S, Osborne C, and Cox D. "An intrinsic antibiotic mechanism in wounds and tissue-engineered skin." J of Invest Dermatol 2001 March; 116:471-472.

Schonfeld WH, et al: "An economic assessment of Apligraf® for the treatment of hard-to-heal venous leg ulcers." Wound RepairRegen 2000;8(4):251-257.

Shen J and Falanga V. "Treatment of venous ulcers using a bi-layered living skin construct." Surg Tech Internat IX , 2000.

Sibbald RG, Torrance GW, Walker V, Attard C and MacNeil P. "Cost-effectiveness of Apligraf® in the treatment of venous leg ulcers." Ostomy Wound Manage 2001 Aug;47(8):36-46.

Sibbald RG. "Apligraf® living skin equivalent for healing venous and chronic wounds." J of Cutan Med Surg 1998;3(suppl 1):S1-24-S1-28.

Steinberg J. "How you can use Apligraf® to treat diabetic foot ulcers?" Podiatry Today, 2000 September.

Steinberg J and Ho T. "Apligraf®: how effective is it?" Podiatry Today, 2001 September.

Still J and Craft-Coffman B. "Graftskin (Apligraf®) in the management of thermal injury." Wounds 2000;12(5 Suppl A):58A-63A.

Streit M and Braathen LR. "Apligraf® - a living human skin equivalent for the treatment of chronic wounds." Int J Artif Organs 2000 Dec;25(12):831-3.

Streit M, et al. "Ulcerative sarcoidosis successfully treated with Apligraf®." Dermatol 2001;202(4):367-370.

Tarlow M, et al. "Effective management of difficult surgical defects using tissue engineered skin." Dermatol Surg 2001;27:71-74.

Teumer J, Hardin-Young J and Parenteau NL. "Tissue Engineered Skin." In: Patrick, Charles W., Jr., Mikos, Antonios G. and McIntire, Larry V., Eds. Frontiers in Tissue Engineering. Elsevier Science Ltd., 1998.

Trent JF and Kirsner RS. "Tissue-engineered skin: Apligraf®, a bi-layered living skin equivalent." Int J Clin Pract. 1998 Sep;52(6):408-413.

Trent, JT and Kirsner RS. "Epidermolysis bullosa: Identification and treatment." Adv in Skin Wound Care 2003;16(6):284-90.

Veves A, et al. "Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial." Diab Care 2001;24(2):290-295.

Waymack P, et al. "The effect of a tissue engineered bi-layered living skin analog, over meshed split-thickness autografts on the healing of excised burn wounds." Burns (UK) 2000;26:609-619.

Wilkins LM, et al. "Development of a bi-layered living skin construct for clinical applications." Biotech Bioeng 1994;43:747-756.

Wilkins LM and Parenteau NL. "Bioengineered skin: Manufacturing, safety, and quality control." In Falanga V, (Ed.) Cutaneous Wound Healing, Martin Dunitz, 2001, pp. 399-410.

Zieske JD, et al. "Basement membrane assembly and differentiation of cultured corneal cells: importance of culture environment and endothelial cell interaction." Exp Cell Res 1994;214:621-633.